Kelsey Stephen Michael 4

What Happened Kelsey Stephen Michael, President, Research and Development at Revolution Medicines (RVMD), sold 4,175 shares on June 16, 2026 in an open-market/private sale for a weighted average price of $156.12, generating about $651,798. The trades were executed under a previously adopted Rule 10b5-1 plan to satisfy tax withholding obligations tied to RSU vesting.

Key Details

• Transaction date: 2026-06-16; Form 4 filed 2026-06-18 (timely).
• Shares sold: 4,175; weighted average price: $156.12; reported total proceeds ≈ $651,798.
• Execution details: multiple trades at prices ranging $156.1105 to $156.8250 (weighted avg reported); reporting person will provide full trade-by-trade info upon request (per filing).
• Footnotes: Sale made pursuant to a 10b5-1 instruction adopted May 31, 2023 to cover tax withholding on RSU vesting after July 15, 2023.
• Holdings noted in filing: includes 76,251 RSUs and 653 shares from the Employee Stock Purchase Plan (ESPP). The report excerpt does not list a single consolidated "shares owned after transaction" total.
• Role: President, Research and Development (reported in Remarks).

Context

• This was a sale executed under a prearranged 10b5-1 plan to satisfy tax-withholding related to restricted stock unit vesting; such transactions are typically routine and done for tax/accounting reasons rather than a direct signal about the insider’s view of the company.
• No options exercise or gift reported in this transaction. The filing does not indicate the reporting person is a 10% owner.